More than $80 million invested

投资超过8,000万美元

to expand and strengthen ESTEVE CDMO's manufacturing capabilities in China.

以拓展并加强ESTEVE CDMO在中国的制造能力。

Three manufacturing workshops and 250 m³ of total reaction volume

三个生产车间，总反应体积为250立方米

, adding new capabilities to our global manufacturing network.

，为全球制造网络增添新能力。

More than 20 years of manufacturing presence in China

在中国拥有二十多年的制造经验

, marking a new chapter in ESTEVE CDMO's long-term commitment to the country.

，标志着ESTEVE CDMO对中国的长期承诺开启了新篇章。

SHAOXING, China

中国绍兴

,

，

Oct. 21, 2026

2026年10月21日

/PRNewswire/ -- ESTEVE CDMO, Esteve's Healthcare contract development and manufacturing organization, is strengthening its global manufacturing footprint through the relocation, expansion and modernization of its existing operations in China, with an investment of more than $80 million.

/美通社/ -- Esteve旗下的医疗保健合同研发与生产组织ESTEVE CDMO正通过搬迁、扩建和现代化改造其在中国的现有业务，投资超过8,000万美元，以加强其全球生产布局。

Continue Reading

继续阅读

Shaoxing Site

绍兴遗址

Sun Xuejie

孙雪洁

The new facility in Shaoxing significantly expands ESTEVE CDMO's manufacturing capabilities in Asia, combining increased capacity, advanced technologies, and flexibility for future growth. It complements the company's established manufacturing network across Europe, the Americas and Asia, strengthening its ability to support pharmaceutical partners worldwide..

位于绍兴的新设施显著拓展了ESTEVE CDMO在亚洲的生产能力，融合了扩大的产能、先进的技术和面向未来增长的灵活性。该设施与公司已在欧洲、美洲和亚洲建立的制造网络相辅相成，进一步强化了其支持全球制药合作伙伴的能力。

'

'

This investment is an important step in the sustained growth of ESTEVE CDMO and our global manufacturing platform. Strengthening our presence in China allows us to bring our capabilities closer to customers in Asia while leveraging the expertise of our global network. Our ambition is clear: to build a leading global CDMO business with the capabilities and flexibility to support our partners worldwide.

此次投资是ESTEVE CDMO持续增长及其全球制造平台发展的重要一步。加强我们在中国的业务布局，使我们能够更贴近亚洲客户，同时依托全球网络的专业优势。我们的目标明确：打造一个领先的全球CDMO企业，具备支持全球合作伙伴所需的能力与灵活性。

This is what drives us: making a difference for patients and contributing to our shared purpose of improving lives together.

这就是我们的动力所在：为患者带来改变，并为实现我们共同改善生活的使命贡献力量。

,' said

“，”说道

Joan Petit, ESTEVE CDMO President.

Joan Petit，ESTEVE CDMO 总裁。

Increased capacity and advanced capabilities

提升的容量与先进功能

The facility includes three manufacturing workshops with a total reaction volume of 250 m³. The facility has been designed with space reserved for an additional 150+ m³, allowing potential total reaction volume to reach 400+ m³ as manufacturing needs evolve. The site includes the necessary service and utility infrastructure to support this future capacity..

该设施包括三个生产车间，总反应体积为250立方米。设施设计时预留了额外150立方米以上的空间，使得随着制造需求的发展，潜在总反应体积可达到400立方米以上。场地内包含支持这一未来产能所需的必要服务和公用基础设施。

Advanced manufacturing, automation and digitalization are integrated throughout the facility, including a purpose-built centralized control center, alongside warehousing facilities, an office building and dedicated infrastructure. This design provides flexibility to expand capacity in line with customer and market needs..

先进制造、自动化和数字化技术在整个工厂中实现深度融合，包括专建的集中控制中心，以及仓储设施、办公楼和专用基础设施。这一设计为根据客户和市场需求灵活扩展产能提供了保障。

As part of ESTEVE CDMO's global technology platform, our China operations complement the capabilities available across our broader manufacturing network. Through this integrated footprint, ESTEVE CDMO offers technologies such as Spray Drying and HPAPI manufacturing, supporting the increasingly complex requirements of small-molecule API development and manufacturing..

作为ESTEVE CDMO全球技术平台的一部分，我们的中国业务与更广泛制造网络中的能力形成互补。凭借这一一体化布局，ESTEVE CDMO提供喷雾干燥和高活性药物成分（HPAPI）生产等技术，支持小分子原料药开发和生产中日益复杂的需求。

Environmental, health, and safety considerations are integrated into the design and operation of the facility. The new site has achieved a 'Very Good' BREEAM rating, recognizing its sustainability performance and approach to responsible design and operation. The project has also been selected as a candidate for the BREEAM China Awards.

环境、健康与安全考量已融入设施的设计与运营之中。新址已获得BREEAM“非常好”评级，以表彰其在可持续性绩效以及负责任的设计与运营方面的表现。该项目还入选了BREEAM中国奖的候选名单。

These efforts are part of ESTEVE's broader commitment to creating positive impact, reinforced by its B Corp Certification and its focus on high standards of social and environmental performance, transparency, and responsible business practices..

这些努力是ESTEVE更广泛承诺的一部分，旨在创造积极影响，并通过其B Corp认证以及对社会和环境绩效、透明度和负责任商业实践的高标准关注而得到加强。

A new chapter after more than two decades in China

在华二十余载后的新篇章

ESTEVE's presence in China dates to 2000, when the company established its first joint venture in the country. Since then, ESTEVE has developed strong local capabilities, expertise, and long-term relationships, becoming an established high-end API manufacturer.

ESTEVE于2000年进入中国市场，当时公司在中国建立了首家合资企业。自那时以来，ESTEVE已发展出强大的本地能力、专业知识和长期合作关系，成为一家成熟的高端原料药制造商。

'

'

It is a privilege to witness ESTEVE's continued commitment to China and the region. This investment is a clear example of the value that long-term commitment, expertise and innovation can bring to the local community,

见证ESTEVE对中国及该地区的持续承诺，我们深感荣幸。这项投资清晰地体现了长期承诺、专业知识和创新能够为当地社区带来的价值。

' said

“说”

Francisco de Asís Benítez Salas, Consul General of Spain in Shanghai.

弗朗西斯科·德阿西斯·贝尼特斯·萨拉斯，西班牙驻上海总领事。

China is an established part of ESTEVE CDMO's global manufacturing network, alongside operations in Spain, Mexico and the United States. The investment builds on more than two decades of local experience and further enhances ESTEVE CDMO's capabilities in China.

中国与西班牙、墨西哥和美国的业务一起，已成为ESTEVE CDMO全球制造网络中成熟的一部分。此次投资建立在二十多年本地经验的基础之上，并进一步提升ESTEVE CDMO在中国的能力。

ESTEVE has two strategic businesses, Pharma and CDMO, united by a shared purpose of Improving lives together. The continued development of ESTEVE CDMO's manufacturing platform strengthens its capabilities, technology and international reach, supporting the long-term needs of pharmaceutical partners..

ESTEVE 拥有两大战略业务板块——制药和合同研发生产组织（CDMO），二者以“携手改善生活”的共同使命紧密相连。ESTEVE CDMO 制造平台的持续发展，进一步强化了其生产能力、技术实力和国际布局，为制药合作伙伴的长期需求提供有力支持。

The investment in China combines ESTEVE CDMO's long-standing local experience with the scale of its global platform, reinforcing its ability to support customers across China, Asia and international markets.

此次对华投资将ESTEVE CDMO深厚的本土经验与其全球平台的规模优势相结合，进一步强化了其支持中国、亚洲及国际市场客户的能力。

About ESTEVE CDMO

关于 ESTEVE CDMO

ESTEVE CDMO, part of Esteve Healthcare, is a global pure-play partner specialized in small-molecule active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, supporting pharmaceutical and biotech innovators in advancing complex molecules from early development to commercial supply. With over 60 years of experience in development and manufacturing, we combine deep scientific expertise, robust regulatory and quality systems, and a collaborative mindset. .

ESTEVE CDMO 隶属于 Esteve Healthcare，是一家全球性的纯合同研发生产组织（CDMO）合作伙伴，专注于小分子活性药物成分（API）和医药中间体，支持制药和生物技术创新者将复杂分子从早期开发推进至商业化供应。凭借六十余年的开发与生产经验，我们融合了深厚的科学专业知识、健全的法规与质量体系以及协作共赢的理念。

ESTEVE CDMO, with headquarters in Barcelona, has a global network of six development and manufacturing sites across Spain, the United States, Mexico, and China, enabling scalable, resilient, and reliable supply solutions, tailored to each program's evolving needs.

ESTEVE CDMO 总部位于巴塞罗那，在全球拥有六个开发和生产基地，分布於西班牙、美国、墨西哥和中国，能够根据每个项目不断变化的需求，提供可扩展、具韧性且可靠的供应解决方案。

About ESTEVE

关于 ESTEVE

ESTEVE

埃斯特韦

is an international healthcare organization with a clear purpose:

是一家国际医疗保健组织，其宗旨明确：

improving lives

改善生活

. This reason for reflecting its commitment to patients, healthcare professionals, communities, and innovators; believing that progress in science and health requires collaboration, shared responsibility, and trust. The company upholds strong ESG (Environment, Social & Governance) standards and is certified as a .

。此举体现了其对患者、医疗保健专业人士、社区及创新者的承诺，坚信科学与健康的进步需要协作、共担责任与信任。该公司恪守高标准的环境、社会及治理（ESG）准则，并获得认证。

B Corp

B Corp

.

。

ESTEVE

埃斯特韦

is focused on serving people living with complex diseases with highly specialized solutions. In parallel, under the

专注于通过高度专业化的解决方案服务于患有复杂疾病的患者。同时，在

ESTEVE CDMO

ESTEVE CDMO

scope, the organization works alongside innovators to accelerate treatments through the development and manufacturing of small-molecule APIs.

在该范围内，本组织与创新者携手合作，通过小分子活性药物成分（API）的开发与生产，加速治疗方案的研发进程。

Founded in 1929 and headquartered in Barcelona, ESTEVE has grown globally, with pharmaceutical affiliates in Europe and the United States; and CDMO facilities in Spain, Mexico, China and the United States.

ESTEVE 成立于1929年，总部位于巴塞罗那，已实现全球化发展，在欧洲和美国设有制药子公司，并在西班牙、墨西哥、中国和美国拥有合同研发生产组织（CDMO）设施。

More information at

更多信息请访问

www.esteve.com

www.esteve.com

.

。

Press contact:

媒体联系人：

Gemma Mestre, Global External Communications Manager,

Gemma Mestre，全球对外传播经理

[email protected]

[email protected]

.

。

SOURCE ESTEVE

来源：ESTEVE

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示